Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.
2/5 보강
TL;DR
Neither BT modality nor response impacted progression‐free or overall survival post‐infusion, so review of haematopoietic reserve prior to the selection of BT regimen, rigorous management of delayed cytopenia post‐infusion and more effective and tolerable BT should be prioritised.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
176 patients at 15 centres in the United Kingdom.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Neither BT modality nor response impacted progression-free or overall survival post-infusion. Review of haematopoietic reserve prior to the selection of BT regimen, rigorous management of delayed cytopenia post-infusion and more effective and tolerable BT should be prioritised.
OpenAlex 토픽 ·
Lymphoma Diagnosis and Treatment
CAR-T cell therapy research
Cutaneous lymphoproliferative disorders research
Neither BT modality nor response impacted progression‐free or overall survival post‐infusion, so review of haematopoietic reserve prior to the selection of BT regimen, rigorous management of delayed c
- p-value p = 0.03
- p-value p = 0.01
- 95% CI 1.44-8.10
APA
Maeve O'Reilly, William Wilson, et al. (2026). Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.. British journal of haematology, 208(4), 1347-1358. https://doi.org/10.1111/bjh.70357
MLA
Maeve O'Reilly, et al.. "Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.." British journal of haematology, vol. 208, no. 4, 2026, pp. 1347-1358.
PMID
41796018 ↗
Abstract 한글 요약
Bridging therapy (BT) prior to brexucabtagene autoleucel (brexu-cel) in mantle cell lymphoma (MCL) is supported by limited evidence. Here, we report BT modality and outcome in 176 patients at 15 centres in the United Kingdom. BT was delivered to 90% (158/176), the majority receiving standard chemotherapy +/- radiotherapy (53%) (SD chemo +/- RT) or targeted therapy (TT) alone (23%). Clinicians favoured SD chemo +/- RT in those with Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 1, blastoid disease, bulk >5 cm and elevated lactate dehydrogenase. Overall response rate (ORR) was 46%. Higher ORR was observed with SD chemo +/- RT (58%), particularly R-BAC (64%). Progressive disease despite BT was associated with a lower ORR to brexu-cel (77% vs. 91%, p = 0.03) and a higher risk of ≥grade 3 ICANS (OR 3.43, 95% CI 1.44-8.10, p = 0.01). SD chemo +/- RT was associated with a higher incidence of ≥grade 3 neutropenia (Month 1), ≥grade 3 thrombocytopenia (Month 1, Month 3) and early non-relapse mortality (<90 days, 13% vs. 0%) compared to TT alone. Neither BT modality nor response impacted progression-free or overall survival post-infusion. Review of haematopoietic reserve prior to the selection of BT regimen, rigorous management of delayed cytopenia post-infusion and more effective and tolerable BT should be prioritised.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.